Syngene International Limited – Board Meeting Highlights (29 April 2026)

Key Financial Highlights (FY 2025‑26)

• Revenue: Consolidated Rs 37.4 bn (+2.6% YoY); Standalone Rs 34.2 bn (+1.5%).
• Net Profit: Consolidated Rs 3.17 bn (‑36% YoY); Standalone Rs 3.05 bn (‑35%).
• Earnings per Share (Annualised): Rs 7.87 (down from Rs 12.35).
• Cash Position: Cash & cash equivalents fell to Rs 2.29 bn from Rs 3.67 bn.
• Dividend: Final dividend of Rs 1.25 per share proposed (record date 26 June 2026).

Board Resolutions

• Audited Results: Approval of audited standalone and consolidated financial statements for the quarter and year ended 31 Mar 2026.
• Statutory Auditor: Appointment of S.R. Batliboi & Associates LLP for a five‑year term (until AGM 2031).
• AGM: 33rd Annual General Meeting scheduled for 29 July 2026.
• Managerial Remuneration: Approval of remuneration for Executive Chairperson Ms. Kiran Mazumdar‑Shaw.

Strategic & Operational Updates

• Capacity Expansion: Continued integration of the US biologics site (acquired in FY 2025) increasing single‑use bioreactor capacity to 50,000 L.
• Licensing: New drug‑substance production line and bonded‑warehouse license obtained for the Bangalore biologics facility.
• Labour Code Impact: Re‑measurement of gratuity obligations under new Indian labour codes resulted in a credit of Rs 229 mn (standalone) / Rs 244 mn (consolidated) for the quarter, partially offsetting earlier exceptional expenses.

Cash Flow Snapshot

• Operating Activities: Net cash from operations fell to Rs 9.15 bn (down from Rs 11.68 bn YoY).
• Investing Activities: Net cash outflow of Rs 8.60 bn, mainly due to capital expenditures and investment in current assets.
• Financing Activities: Net cash outflow of Rs 2.15 bn, reflecting dividend payout and short‑term borrowing repayments.

Investor Implications

• Positive: Revenue growth, dividend payout, capacity expansion, and stable audit governance.
• Negative: Significant profit contraction, declining cash reserves, higher operating costs, and exposure to foreign‑exchange fluctuations.
• Risk Factors: Margin pressure, cash‑flow sustainability, regulatory changes (labour codes), and execution risk of capacity‑expansion projects.
• Opportunities: Growing global demand for contract research and biologics manufacturing, potential upside from newly licensed facilities, and long‑term dividend income.

Prepared on 29 April 2026 for investors reviewing Syngene International’s latest corporate disclosures.